Patritumab deruxtecan
Phase 1/2Recruiting 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastrointestinal Cancer
Conditions
Gastrointestinal Cancer
Trial Timeline
Nov 3, 2024 → Dec 7, 2028
NCT ID
NCT06596694About Patritumab deruxtecan
Patritumab deruxtecan is a phase 1/2 stage product being developed by Daiichi Sankyo for Gastrointestinal Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06596694. Target conditions include Gastrointestinal Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05620914 | Phase 2 | Withdrawn |
| NCT06941272 | Phase 1/2 | Recruiting |
| NCT06596694 | Phase 1/2 | Recruiting |
| NCT05865990 | Phase 2 | Active |
| NCT04479436 | Phase 2 | Terminated |
| NCT02980341 | Phase 1/2 | Completed |
Competing Products
20 competing products in Gastrointestinal Cancer